Optimizing Biopharma Commercial Strategy and Patient Support Programs
Dean Erhardt, CEO of D2 Solutions, discusses critical gaps in the biopharmaceutical industry's patient onboarding process in an interview with Pharmaceutical Executive. Recent survey data reveals that only 20% of patients describe their medication start experience as strong, while nearly half report anxiety or confusion due to fragmented communication among providers, payers, and pharmacies. Erhardt highlights that younger generations, particularly Millennials, are significantly less tolerant of administrative friction, leading to higher rates of therapy abandonment when processes are opaque. The article emphasizes that the current system is designed around transactions rather than patient experience, causing disengagement before treatment begins. To address these issues, Erhardt advocates for increased transparency during the prescription-to-fulfillment period, better coordination across stakeholders, and proactive management of delays. He argues that improving visibility and simplifying navigation are essential not just for access, but for ensuring patients initiate and adhere to prescribed therapies. The discussion underscores the urgent need for a connected, patient-centered approach to prevent negative health outcomes driven by systemic inefficiencies.
Wire timeline
Optimizing Biopharma Commercial Strategy and Patient Support Programs
Dean Erhardt, CEO of D2 Solutions, discusses critical gaps in the biopharmaceutical industry's patient onboarding process in an interview with Pharmaceutical Executive. Recent survey data reveals that only 20% of patients describe their medication start experience as strong, while nearly half report anxiety or confusion due to fragmented communication among providers, payers, and pharmacies. Erhardt highlights that younger generations, particularly Millennials, are significantly less tolerant of administrative friction, leading to higher rates of therapy abandonment when processes are opaque. The article emphasizes that the current system is designed around transactions rather than patient experience, causing disengagement before treatment begins. To address these issues, Erhardt advocates for increased transparency during the prescription-to-fulfillment period, better coordination across stakeholders, and proactive management of delays. He argues that improving visibility and simplifying navigation are essential not just for access, but for ensuring patients initiate and adhere to prescribed therapies. The discussion underscores the urgent need for a connected, patient-centered approach to prevent negative health outcomes driven by systemic inefficiencies.
PharmExec articles